In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Power: How The Crowd May Shape The Funding And Development Of Drugs

Executive Summary

Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.

You may also be interested in...



FDA Acquires Trove Of Rx Safety Data Through Alliance With PatientsLikeMe

Research collaboration will give FDA access to individual drug safety reports from patient network’s 350,000 members and could lead to future projects on post-market surveillance.

Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese

Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.

Financings Of The Fortnight Looks To The High-Tech Sector For New Life-Science Capital Sources

Plus news on recent financings by Elcelyx, Jounce Therapeutics, Retrophin and e-Therapeutics.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel